Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor

dc.contributor.author Kalle, Arunasree M.
dc.contributor.author Rizvi, Arshad
dc.date.accessioned 2022-03-27T01:02:21Z
dc.date.available 2022-03-27T01:02:21Z
dc.date.issued 2011-01-01
dc.description.abstract Multidrug resistance (MDR) is a major problem in the treatment of infectious diseases and cancer. Accumulating evidence suggests that the cyclooxygenase-2 (COX-2)-specific inhibitor celecoxib would not only inhibit COX-2 but also help in the reversal of drug resistance in cancers by inhibiting the MDR1 efflux pump. Here, we demonstrate that celecoxib increases the sensitivity of bacteria to the antibiotics ampicillin, kanamycin, chloramphenicol, and ciprofloxacin by accumulating the drugs inside the cell, thus reversing MDR in bacteria. Copyright © 2011 American Society for Microbiology. All Rights Reserved.
dc.identifier.citation Antimicrobial Agents and Chemotherapy. v.55(1)
dc.identifier.issn 00664804
dc.identifier.uri 10.1128/AAC.00735-10
dc.identifier.uri https://journals.asm.org/doi/10.1128/AAC.00735-10
dc.identifier.uri https://dspace.uohyd.ac.in/handle/1/3949
dc.title Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor
dc.type Journal. Article
dspace.entity.type
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description: